



**Department of Vermont Health Access  
Pharmacy Benefits Management Program  
*DUR Board Meeting Agenda***

---

December 5, 2023: 6:00 – 8:30 p.m.

- **Executive Session** **6:00 - 6:30**
- **Introductions and Approval of DUR Board Minutes** **6:30 - 6:35**  
(Public Comment Prior to Board Action)
- **DVHA Pharmacy Administration Updates** **6:35 - 6:50**
  - Gold Card Report
- **Chief Medical Officer Updates** **6:50 - 6:55**
- **Follow-up Items from Previous Meetings** **6:55 – 7:00**
  - Xeljanz® (tofacitinib) oral solution
  - Kesimpta® (ofatumumab)
  - Cabenuva (cabotegravir/rilpivirine)
- **RetroDUR/ProDUR** **7:00- 7:25**
  - Data presentation: *“Triple Therapy”: Opioids, Benzodiazepines, and Skeletal Muscle Relaxants*
- **Clinical Update: Drug Reviews** **7:25-7:45**  
(Public comment prior to Board action)
  - **Biosimilar Drug Reviews**
    - None at this time.
  - **Full New Drug Reviews**  
(Any new drug reviews that also fall within the Therapeutic Class Review (TCR) will be discussed during the Therapeutic Class Review)
    - Abilify Asimtufii® (aripiprazole) and Uzedly® (risperidone)
    - Inpefa® (sotagliflozin)
    - Liqrev® (sildenafil)
    - Konvomep® (omeprazole and sodium bicarbonate)
    - Qalsody® (tofersen)
    - Rebyota™ (fecal microbiota, live- jslm) and Vowst™ (fecal microbiota spores, live-brpk)
    - Syfovre® (pegcetacoplan)
    - Veozah™ (fezolinetant)
    - Zavzpret™ (zavegepant)
- **New Managed Therapeutic Drug Classes** **7:45 -7:55**

- Ophthalmic, Anti-VEGF and Miscellaneous Agents (new drug Syfovre® (pegcetacoplan) included)  
(Public comment prior to Board action)
  
- **Therapeutic Drug Classes – Periodic Review** **7:55 - 8:30**  
(Public comment prior to Board action)
  - Gastrointestinal Ulcer Therapies (new drug Konvomep® (omeprazole and sodium bicarbonate) included)
  - H. Pylori Combination Treatments
  - Hyperuricemia and Gout
  - Ophthalmic, Allergic Conjunctivitis
  - Ophthalmic, Antibiotics
  - Ophthalmic, Anti-Inflammatories
  - Ophthalmic, Dry Eye Treatments
  - Ophthalmic, Glaucoma Agents
  - Platelet Aggregation Inhibitors
  
- **Review of Newly Developed/Revised Criteria** **8:30 - 8:30**  
(Public comment prior to Board action)
  - None at this time.
  
- **General Announcements** **8:30 – 8:30**
  - None at this time.
  
- **Adjourn** **8:30**